Optimizing the crystal size and habit of β-sitosterol in suspension

AAPS PharmSciTech

Volumn 4, Issue 3, 2003, Pages

  von Bonsdorff Nikander, Anna ^a   Rantanen, Jukka ^a   Christiansen, Leena ^a   Yliruusi, Jouko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Crystal habit; Crystal size; Microcrystalline; sitosterol

Indexed keywords

POLYSORBATE 80; SITOSTEROL; SITOSTEROL DERIVATIVE; SURFACTANT;

ARTICLE; CONTROLLED STUDY; COOLING; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; LOW TEMPERATURE PROCEDURES; MICROSCOPY; PARTICLE SIZE; PROCESS OPTIMIZATION; RADIATION SCATTERING; ROOM TEMPERATURE; SUSPENSION; TIME; X RAY DIFFRACTION; CHEMISTRY; COLD; METABOLISM; METHODOLOGY; TEMPERATURE;

CHEMISTRY, PHARMACEUTICAL; COLD; CRYSTALLIZATION; PARTICLE SIZE; SITOSTEROLS; SURFACE-ACTIVE AGENTS; SUSPENSIONS; TEMPERATURE; TIME FACTORS; X-RAY DIFFRACTION;

EID: 17944402193     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt040344     Document Type: Article

References (31)

1. Mackellar AJ, Buckton G, Newton JM, Chowdhry BZ, Orr CA. The controlled crystallisation of a model powder. I. The effects of altering the stirring rate and the supersaturation profile and the incorporation of a surfactant (Poloxamer 188). Int J Pharm. 1994;112:65-78.
2. Mullin JW. Crystallization. Oxford, UK: Butterworth-Heinemann; 2000.
3. Florence AT, Attwood D. Physicochemical Principles of Pharmacy. Basingstoke, UK: Macmillan Press Ltd; 1998.
4. Myerson AS, Ginde R. Crystals, crystal growth and nucleation. In: Handbook of Industrial Crystallization. St Louis, MO: Butter-worth-Heinemann;1993:33-63.
5. Boistelle R, Astier JP. Crystallization mechanisms in solution. J Cryst Growth. 1988;90:14-30.
6. Schüth F. Nucleation and crystallization of solids from solutions. Curr Opin Solid State Mater Sci. 2001;5:389-395.
7. Zipp GL, Rodríguez-Hornedo N. The mechanism of phenytoin crystal growth. Int J Pharm. 1993;98:189-201.
8. Sunada H, Yamamoto A, Otsuka A, Yonezawa Y. Changes of surface area in the dissolution process of crystalline substances. Chem Pharm Bull. 1987;36(7):2557-2561.
9. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47-60.
10. Rasenack N, Hartenhauer H, Müller BW. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm. 2003;254:137-145.
11. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91-97.
12. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18:113-120.
13. Mattson GM, Volpenheim FA, Erickson BA. Effect of plant sterol esters on the absorption of dietary cholesterol. J Nutr. 1997;107:1139-1146.
14. Christiansen LI, Rantanen JT, von Bonsdorff AK, Karjalainen MA, Yliruusi JK. A novel method of producing a microcrystalline β-sitosterol suspension in oil. Eur J Pharm Sci. 2001;15:261-269.
15. Christiansen LI, Lähteenmäki PLA, Mannelin MR, Seppänen-Laakso TE, Hiltunen RVK, Yliruusi JK. Cholesterol-lowering effect of spreads enriched with microcrystalline plant sterols in hypercholesterolemic subjects. Eur J Nutr. 2001;40:66-73.
16. von Bonsdorff-Nikander A, Karjalainen M, Rantanen J, Christiansen L, Yliruusi J. Physical stability of a microcrystalline β-sitosterol suspension in oil. Eur J Pharm Sci. 2003;19:173-179.
17. Jones AG, Mullin JW. Programmed cooling crystallization of potassium sulphate solutions. Chem Eng Sci. 1974;29:105-118.
18. Mullin JW, Raven KD. Nucleation in agitated solutions. Nature. 1961;190:251.
19. Dogua J, Simon B. Crystallization of sodium perborate from aqueous solution. J Cryst Growth. 1978;44:265-279.
20. Viaene J, Januszewska R. Quality function deployment in the chocolate industry. Food Quality and Preference. 1999;10:377-385.
21. Tyle P. Effect of size, shape and hardness of particles in suspension on oral texture and palatability. Acta Psychologica. 1993;84:111-118.
22. Mazzarotta B, Si Cave S, Bonifazi G. Influence of time on crystal attrition in a stirred vessel. AIChE J. 1996;42 (12):3554-3558.
23. Gibaldi M. Biopharmaceutics. In: Lachman L, Lieberman HA, Kanig JL, eds. The Theory and Practice of Industrial Pharmacy. 2nd ed. Philadelphia, PA: Lea & Febiger; 1976: 78-140.
24. Bisrat M, Nyström C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm. 1988;47:223-231.
25. Anderberg EK, Bisrat M, Nyström C. Physicochemical aspects of drug release. VII. The effect of surfactant concentration and drug particle size on solubility and dissolution rate of felodipine, a sparingly soluble drug. Int J Pharm. 1988;47:67-77.
26. Rauls M, Bartosch K, Kind M, Kuch S, Racmann R, Mersmann A. The influence of impurities on crystallization kinetics - a case study on ammonium sulfate. J Cryst Growth. 2000;213:116-128.
27. El-Bary AA, Kassem MAA, Foda N, Travel S, Badawi SS. Controlled crystallization of chlorpropamide from surfactant and polymer solutions. Drug Dev Ind Pharm. 1990;16(10):1649-1660.
28. Mackellar AJ, Buckton G, Newton JM, Orr CA. The controlled crystallization of a model powder. II. Investigation into the mechanism of action of poloxamers in changing crystal properties. Int J Pharm. 1994;112:79-85.
29. Kim CA, Choi HK. Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix. Int J Pharm. 2002;236:81-85.
30. Luhtala S. Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth and aqueous solubility of carbamazepine. Acta Pharm Nord. 1992;4(2):85-90.
31. Canselier JP. The effects of surfactants on crystallization phenomena. J Dispersion Sci Technol. 1993;14(6):625-644.